Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly in the immensely lucrative weight-loss drug market, said it is partnering with OpenAI to deploy artificial intelligence across its business, from drug discovery to manufacturing and commercial operations…— Reuters (@Reuters) April 14, 2026
Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly in the immensely lucrative weight-loss drug market, said it is partnering with OpenAI to deploy artificial intelligence across its business, from drug discovery to manufacturing and commercial operations…
@Reuters·X: @Reuters··1 min read
X
Continue reading on X: @Reuters
This article was sourced from X: @Reuters's RSS feed. Visit the original for the complete story.